{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:18:37Z","timestamp":1793017117757,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH\/NCI","award":["R25CA180993"],"award-info":[{"award-number":["R25CA180993"]}]},{"DOI":"10.13039\/100005188","name":"Tobacco-Related Disease Research Program","doi-asserted-by":"publisher","award":["T29FT0569"],"award-info":[{"award-number":["T29FT0569"]}],"id":[{"id":"10.13039\/100005188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Malignant pleural effusions (MPEs) can be utilized as liquid biopsy for phenotyping malignant cells and for precision immunotherapy, yet MPEs are inadequately studied at the single-cell proteomic level. Here we leverage mass cytometry to interrogate immune and epithelial cellular profiles of primary tumors and\u00a0pleural effusions (PEs) from early and late-stage non-small cell lung cancer\u00a0(NSCLC) patients, with the goal of assessing epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) states in patient specimens. By using the EMT\u2013MET reference map PHENOSTAMP, we observe a variety of EMT states in cytokeratin positive (CK+) cells, and report for the first time MET-enriched CK+ cells in MPEs. We show that these states may be relevant to disease stage and therapy response. Furthermore, we found that the fraction of CD33+ myeloid cells in\u00a0PEs was positively correlated to the fraction of CK+ cells. Longitudinal analysis of MPEs drawn 2 months apart from a patient undergoing therapy, revealed that CK+ cells acquired heterogeneous EMT features during treatment. We present this work as a feasibility study that justifies deeper characterization of EMT and MET states in malignant cells found in PEs as a promising clinical platform to better evaluate disease progression and treatment response at a personalized level.<\/jats:p>","DOI":"10.1038\/s41598-023-46458-5","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T18:02:20Z","timestamp":1702058540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry"],"prefix":"10.1038","volume":"13","author":[{"given":"Loukia G.","family":"Karacosta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Pancirer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan S.","family":"Preiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalen A.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Trope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph B.","family":"Shrager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur Wai","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel W.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean C.","family":"Bendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia K.","family":"Plevritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"46458_CR1","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1172\/JCI39104","volume":"119","author":"R Kalluri","year":"2009","unstructured":"Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420\u20131428 (2009).","journal-title":"J. Clin. Invest."},{"key":"46458_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","volume":"19","author":"LA Byers","year":"2013","unstructured":"Byers, L. A. et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19, 279\u2013290 (2013).","journal-title":"Clin. Cancer Res."},{"key":"46458_CR3","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1158\/0008-5472.CAN-14-2535","volume":"75","author":"MJ Schliekelman","year":"2015","unstructured":"Schliekelman, M. J. et al. Molecular portraits of epithelial, mesenchymal, and hybrid states in lung adenocarcinoma and their relevance to survival. Cancer Res. 75, 1789\u20131800 (2015).","journal-title":"Cancer Res."},{"key":"46458_CR4","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1158\/1541-7786.MCR-10-0568","volume":"9","author":"D Yao","year":"2011","unstructured":"Yao, D., Dai, C. & Peng, S. Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol. Cancer Res. 9, 1608\u20131620 (2011).","journal-title":"Mol. Cancer Res."},{"key":"46458_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10555-012-9377-5","volume":"31","author":"NPAD Gunasinghe","year":"2012","unstructured":"Gunasinghe, N. P. A. D., Wells, A., Thompson, E. W. & Hugo, H. J. Mesenchymal\u2013epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev. 31, 469\u2013478 (2012).","journal-title":"Cancer Metastasis Rev."},{"key":"46458_CR6","doi-asserted-by":"publisher","first-page":"5996","DOI":"10.1158\/0008-5472.CAN-05-0699","volume":"65","author":"D Tarin","year":"2005","unstructured":"Tarin, D. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 65, 5996\u20136001 (2005).","journal-title":"Cancer Res"},{"key":"46458_CR7","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41568-019-0213-x","volume":"19","author":"ED Williams","year":"2019","unstructured":"Williams, E. D., Gao, D., Redfern, A. & Thompson, E. W. Controversies around epithelial\u2013mesenchymal plasticity in cancer metastasis. Nat. Rev. Cancer 19, 716\u2013732 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"46458_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-018-0040-3","volume":"556","author":"I Pastushenko","year":"2018","unstructured":"Pastushenko, I. et al. Identification of the tumour transition states occurring during EMT. Nature 556, 463\u2013468 (2018).","journal-title":"Nature"},{"key":"46458_CR9","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.celrep.2018.01.053","volume":"22","author":"VD Gonzalez","year":"2018","unstructured":"Gonzalez, V. D. et al. Commonly occurring cell subsets in high-grade serous ovarian tumors identified by single-cell mass cytometry. Cell Rep. 22, 1875\u20131888 (2018).","journal-title":"Cell Rep."},{"key":"46458_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12307-011-0085-4","volume":"5","author":"Y Chao","year":"2012","unstructured":"Chao, Y., Wu, Q., Acquafondata, M., Dhir, R. & Wells, A. Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases. Cancer Microenviron. 5, 19\u201328 (2012).","journal-title":"Cancer Microenviron."},{"key":"46458_CR11","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1038\/s41467-019-13441-6","volume":"10","author":"LG Karacosta","year":"2019","unstructured":"Karacosta, L. G. et al. Mapping lung cancer epithelial-mesenchymal transition states and trajectories with single-cell resolution. Nat. Commun. 10, 5587 (2019).","journal-title":"Nat. Commun."},{"key":"46458_CR12","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1002\/jcp.29121","volume":"235","author":"S Bruschini","year":"2020","unstructured":"Bruschini, S. et al. CytoMatrix for a reliable and simple characterization of lung cancer stem cells from malignant pleural effusions. J. Cell. Physiol. 235, 1877\u20131887 (2020).","journal-title":"J. Cell. Physiol."},{"key":"46458_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2147\/CMAR.S95663","volume":"9","author":"E Penz","year":"2017","unstructured":"Penz, E., Watt, K. N., Hergott, C. A., Rahman, N. M. & Psallidas, I. Management of malignant pleural effusion: Challenges and solutions. Cancer Manag. Res. 9, 229\u2013241 (2017).","journal-title":"Cancer Manag. Res."},{"key":"46458_CR14","doi-asserted-by":"publisher","first-page":"OT1","DOI":"10.1158\/1538-7445.SABCS16-OT1-01-01","volume":"77","author":"J Watanabe","year":"2017","unstructured":"Watanabe, J., Ohtani, S., Ikeda, M., Takahashi, M. & Moriya, T. Abstract OT1-01-01: A phase II, open-label, multicenter, translational study for biomarkers of eribulin mesylate: Evaluation of the utility of monitoring epithelial-to-mesenchymal transition (EMT) markers on tumor cells in the malignant plural effusion of patients with metastatic breast cancer (EXPECT-study). Cancer Res. 77, OT1 (2017).","journal-title":"Cancer Res."},{"key":"46458_CR15","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.3390\/cancers13112798","volume":"13","author":"MA Sorolla","year":"2021","unstructured":"Sorolla, M. A., Sorolla, A., Parisi, E., Salud, A. & Porcel, J. M. Diving into the pleural fluid: Liquid biopsy for metastatic malignant pleural effusions. Cancers 13, 2798 (2021).","journal-title":"Cancers"},{"key":"46458_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.lungcan.2018.11.020","volume":"127","author":"JC Thompson","year":"2019","unstructured":"Thompson, J. C. et al. Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients. Lung Cancer 127, 25\u201333 (2019).","journal-title":"Lung Cancer"},{"key":"46458_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.lungcan.2016.04.015","volume":"107","author":"LA Lievense","year":"2017","unstructured":"Lievense, L. A. et al. Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients. Lung Cancer 107, 36\u201340 (2017).","journal-title":"Lung Cancer"},{"key":"46458_CR18","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ajpath.2010.12.003","volume":"178","author":"J-M Hou","year":"2011","unstructured":"Hou, J.-M. et al. Circulating tumor cells as a window on metastasis biology in lung cancer. Am. J. Pathol. 178, 989\u2013996 (2011).","journal-title":"Am. J. Pathol."},{"key":"46458_CR19","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1002\/cam4.556","volume":"4","author":"T Sowa","year":"2015","unstructured":"Sowa, T. et al. Association between epithelial-mesenchymal transition and cancer stemness and their effect on the prognosis of lung adenocarcinoma. Cancer Med. 4, 1853\u20131862 (2015).","journal-title":"Cancer Med."},{"key":"46458_CR20","doi-asserted-by":"publisher","first-page":"e0160807","DOI":"10.1371\/journal.pone.0160807","volume":"11","author":"C Ruiz","year":"2016","unstructured":"Ruiz, C. et al. Culture and drug profiling of patient derived malignant pleural effusions for personalized cancer medicine. PLOS ONE 11, e0160807 (2016).","journal-title":"PLOS ONE"},{"key":"46458_CR21","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomaterials.8b01356","author":"A Mazzocchi","year":"2019","unstructured":"Mazzocchi, A. et al. Pleural effusion aspirate for use in 3D lung cancer modeling and chemotherapy screening. ACS Biomater. Sci. Eng. https:\/\/doi.org\/10.1021\/acsbiomaterials.8b01356 (2019).","journal-title":"ACS Biomater. Sci. Eng."},{"key":"46458_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nbt.4314","volume":"37","author":"E Becht","year":"2019","unstructured":"Becht, E. et al. Dimensionality reduction for visualizing single-cell data using UMAP. Nat. Biotechnol. 37, 38\u201344 (2019).","journal-title":"Nat. Biotechnol."},{"key":"46458_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.trecan.2015.07.006","volume":"1","author":"N Aceto","year":"2015","unstructured":"Aceto, N., Toner, M., Maheswaran, S. & Haber, D. A. En route to metastasis: Circulating tumor cell clusters and epithelial-to-mesenchymal transition. Trends Cancer 1, 44\u201352 (2015).","journal-title":"Trends Cancer"},{"key":"46458_CR24","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1158\/1078-0432.CCR-14-0894","volume":"21","author":"A Satelli","year":"2015","unstructured":"Satelli, A. et al. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin. Cancer Res. 21, 899\u2013906 (2015).","journal-title":"Clin. Cancer Res."},{"key":"46458_CR25","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.21037\/jtd.2017.09.63","volume":"9","author":"N Sawabata","year":"2017","unstructured":"Sawabata, N. Circulating tumor cells in lung cancer: Cluster circulating tumor cells as hybrid epithelial-mesenchymal transition\/mesenchymal-epithelial transition (E\/M). J. Thorac. Dis. 9, 3547\u20133550 (2017).","journal-title":"J. Thorac. Dis."},{"key":"46458_CR26","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1038\/bjc.2011.405","volume":"105","author":"A Lecharpentier","year":"2011","unstructured":"Lecharpentier, A. et al. Detection of circulating tumour cells with a hybrid (epithelial\/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br. J. Cancer 105, 1338\u20131341 (2011).","journal-title":"Br. J. Cancer"},{"key":"46458_CR27","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar, V., Patel, S., Tcyganov, E. & Gabrilovich, D. I. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 37, 208\u2013220 (2016).","journal-title":"Trends Immunol."},{"key":"46458_CR28","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DAE Cross","year":"2014","unstructured":"Cross, D. A. E. et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4, 1046\u20131061 (2014).","journal-title":"Cancer Discov."},{"key":"46458_CR29","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.jtho.2017.07.011","volume":"12","author":"KS Thress","year":"2017","unstructured":"Thress, K. S. et al. Modulation of biomarker expression by osimertinib: Results of the paired tumor biopsy cohorts of the AURA phase I trial. J. Thorac. Oncol. 12, 1588\u20131594 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"46458_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-018-0346-4","volume":"39","author":"X Guan","year":"2019","unstructured":"Guan, X. et al. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial\u2013mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Cancer Commun. 39, 1 (2019).","journal-title":"Cancer Commun."},{"key":"46458_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3109\/14767058.2011.613159","volume":"24","author":"D Fanni","year":"2011","unstructured":"Fanni, D. et al. MUC1 in mesenchymal-to-epithelial transition during human nephrogenesis: Changing the fate of renal progenitor\/stem cells?. J. Matern. Fetal Neonatal Med. 24, 63\u201366 (2011).","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"46458_CR32","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1080\/19336918.2016.1155019","volume":"10","author":"G Hamilton","year":"2016","unstructured":"Hamilton, G., Hochmair, M., Rath, B., Klameth, L. & Zeillinger, R. Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype. Cell Adhesion Migr. 10, 360\u2013367 (2016).","journal-title":"Cell Adhesion Migr."},{"key":"46458_CR33","doi-asserted-by":"publisher","first-page":"29991","DOI":"10.18632\/oncotarget.5031","volume":"6","author":"KN Chua","year":"2015","unstructured":"Chua, K. N. et al. Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma. Oncotarget 6, 29991\u201330005 (2015).","journal-title":"Oncotarget"},{"key":"46458_CR34","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1111\/febs.14084","volume":"284","author":"K Manupati","year":"2017","unstructured":"Manupati, K. et al. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal\u2013epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs. FEBS J. 284, 1830\u20131854 (2017).","journal-title":"FEBS J."},{"key":"46458_CR35","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.3390\/cells9051218","volume":"9","author":"M Abreu","year":"2020","unstructured":"Abreu, M. et al. Circulating tumor cells characterization revealed TIMP1 as a potential therapeutic target in ovarian cancer. Cells 9, 1218 (2020).","journal-title":"Cells"},{"key":"46458_CR36","doi-asserted-by":"publisher","first-page":"48820","DOI":"10.18632\/oncotarget.16179","volume":"8","author":"I Chebouti","year":"2017","unstructured":"Chebouti, I. et al. EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy. Oncotarget 8, 48820\u201348831 (2017).","journal-title":"Oncotarget"},{"key":"46458_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5732\/cjc.010.10239","volume":"30","author":"J-P Cheng","year":"2011","unstructured":"Cheng, J.-P. et al. MUC1-positive circulating tumor cells and MUC1 protein predict chemotherapeutic efficacy in the treatment of metastatic breast cancer. Chin J. Cancer 30, 54\u201361 (2011).","journal-title":"Chin J. Cancer"},{"key":"46458_CR38","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1038\/oncsis.2013.16","volume":"2","author":"S Nath","year":"2013","unstructured":"Nath, S. et al. MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes. Oncogenesis 2, e51\u2013e51 (2013).","journal-title":"Oncogenesis"},{"key":"46458_CR39","doi-asserted-by":"publisher","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-13-3168","volume":"20","author":"A Kharbanda","year":"2014","unstructured":"Kharbanda, A. et al. Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells. Clin. Cancer Res. 20, 5423\u20135434 (2014).","journal-title":"Clin. Cancer Res."},{"key":"46458_CR40","doi-asserted-by":"publisher","first-page":"e1438","DOI":"10.1038\/cddis.2014.421","volume":"5","author":"Q Zhao","year":"2014","unstructured":"Zhao, Q. et al. MUC1 extracellular domain confers resistance of epithelial cancer cells to anoikis. Cell Death Dis. 5, e1438\u2013e1438 (2014).","journal-title":"Cell Death Dis."},{"key":"46458_CR41","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1097\/JTO.0b013e31817c6b4f","volume":"3","author":"R Ramlau","year":"2008","unstructured":"Ramlau, R. et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III\/IV non-small cell lung cancer. J. Thorac. Oncol. 3, 735\u2013744 (2008).","journal-title":"J. Thorac. Oncol."},{"key":"46458_CR42","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/ijc.28478","volume":"134","author":"DP Freitas","year":"2014","unstructured":"Freitas, D. P., Teixeira, C. A., Santos-Silva, F., Vasconcelos, M. H. & Almeida, G. M. Therapy-induced enrichment of putative lung cancer stem-like cells. Int. J. Cancer 134, 1270\u20131278 (2014).","journal-title":"Int. J. Cancer"},{"key":"46458_CR43","doi-asserted-by":"publisher","first-page":"14979","DOI":"10.1038\/ncomms14979","volume":"8","author":"M Ouzounova","year":"2017","unstructured":"Ouzounova, M. et al. Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade. Nat. Commun. 8, 14979 (2017).","journal-title":"Nat. Commun."},{"key":"46458_CR44","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1158\/0008-5472.CAN-11-2905","volume":"72","author":"D Gao","year":"2012","unstructured":"Gao, D. et al. Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res. 72, 1384\u20131394 (2012).","journal-title":"Cancer Res."},{"key":"46458_CR45","first-page":"175","volume":"41","author":"BJ Wu","year":"2019","unstructured":"Wu, B. J., Wang, Z., Dong, Y., Deng, Y. L. & Shi, Q. H. Identification and single-cell sequencing analysis of rare tumor cells in malignant pleural effusion of lung cancer patients. Yi Chuan 41, 175\u2013184 (2019).","journal-title":"Yi Chuan"},{"key":"46458_CR46","doi-asserted-by":"publisher","first-page":"e1554969","DOI":"10.1080\/2162402X.2018.1554969","volume":"8","author":"P Murthy","year":"2019","unstructured":"Murthy, P. et al. Making cold malignant pleural effusions hot: Driving novel immunotherapies. OncoImmunology 8, e1554969 (2019).","journal-title":"OncoImmunology"},{"key":"46458_CR47","first-page":"29","volume":"45","author":"J Wlosik","year":"2023","unstructured":"Wlosik, J. et al. Immune biology of NSCLC revealed by single-cell technologies: Implications for the development of biomarkers in patients treated with immunotherapy. Semin. Immunopathol. 45, 29\u201341 (2023).","journal-title":"Semin. Immunopathol."},{"key":"46458_CR48","first-page":"3538","volume":"38","author":"FP Carneiro","year":"2017","unstructured":"Carneiro, F. P. et al. A panel of markers for identification of malignant and non-malignant cells in culture from effusions. Oncol. Rep. 38, 3538\u20133544 (2017).","journal-title":"Oncol. Rep."},{"key":"46458_CR49","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1513\/AnnalsATS.201303-068OC","volume":"10","author":"DE Schwed Lustgarten","year":"2013","unstructured":"Schwed Lustgarten, D. E. et al. Use of circulating tumor cell technology (CELLSEARCH) for the diagnosis of malignant pleural effusions. Ann. ATS 10, 582\u2013589 (2013).","journal-title":"Ann. ATS"},{"key":"46458_CR50","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1111\/cas.14821","volume":"112","author":"IT Nakamura","year":"2021","unstructured":"Nakamura, I. T. et al. Development of an optimal protocol for molecular profiling of tumor cells in pleural effusions at single-cell level. Cancer Sci. 112, 2006\u20132019 (2021).","journal-title":"Cancer Sci."},{"key":"46458_CR51","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1479-5876-9-70","volume":"9","author":"Z Liu","year":"2011","unstructured":"Liu, Z. et al. Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients. J. Transl. Med. 9, 70 (2011).","journal-title":"J. Transl. Med."},{"key":"46458_CR52","unstructured":"Zhu, Y. et al. Identification and characterization of effusion tumor cells (ETCs) from remnant pleural effusion specimens. Cancer Cytopathology n\/a."},{"key":"46458_CR53","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.3748\/wjg.v10.i16.2406","volume":"10","author":"D-N He","year":"2004","unstructured":"He, D.-N. et al. E-cadherin and calretinin as immunocytochemical markers to differentiate malignant from benign serous effusions. World J. Gastroenterol. 10, 2406\u20132408 (2004).","journal-title":"World J. Gastroenterol."},{"key":"46458_CR54","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/(SICI)1097-0142(19971025)81:5<293::AID-CNCR7>3.0.CO;2-O","volume":"81","author":"K Schofield","year":"1997","unstructured":"Schofield, K., D\u2019Aquila, T. & Rimm, D. L. The cell adhesion molecule, E-cadherin, distinguishes mesothelial cells from carcinoma cells in fluids. Cancer Cytopathol. 81, 293\u2013298 (1997).","journal-title":"Cancer Cytopathol."},{"key":"46458_CR55","first-page":"377","volume":"57","author":"JS Cho","year":"2013","unstructured":"Cho, J. S. et al. Diagnostic usefulness of MUC1 and MUC4 for distinguishing between metastatic adenocarcinoma cells and reactive mesothelial cells in effusion cell blocks. ACY 57, 377\u2013383 (2013).","journal-title":"ACY"},{"key":"46458_CR56","volume-title":"Pleural Effusion","author":"R Krishna","year":"2023","unstructured":"Krishna, R., Antoine, M. H. & Rudrappa, M. Pleural Effusion (StatPearls Publishing, 2023)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46458-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46458-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46458-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T18:07:11Z","timestamp":1702058831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46458-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["46458"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-46458-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]},"assertion":[{"value":"7 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21781"}}